NCT02723864: Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors

NCT02723864
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Misc Inhibitor, Chemotherapy, Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 110 Years(Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with known active unstable brain metastases or carcinomatous meningitis- see trial for details
https://ClinicalTrials.gov/show/NCT02723864

Comments are closed.

Up ↑